Company Overview of Advaxis, Inc.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, completed its Phase II study. The company is also develop...
305 College Road East
Princeton, NJ 08540
Founded in 2002
Key Executives for Advaxis, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $398.8K
Chief Operating Officer and Executive Vice President
Total Annual Compensation: $285.0K
Chief Scientific Officer and Executive Vice President
Total Annual Compensation: $331.2K
Compensation as of Fiscal Year 2014.
Advaxis, Inc. Key Developments
Advaxis, Inc. Announces Licensing Agreement with Knight Therapeutics Inc
Aug 26 15
Advaxis, Inc. announced that the company has entered into a licensing agreement with Knight Therapeutics Inc. to commercialize in Canada Advaxis's product portfolio including its three lead drug candidates: axalimogene filolisbac (ADXS-HPV) for human papilloma virus (HPV)-associated cancers, ADXS-PSA for prostate cancer and ADXS-HER2 for HER2 expressing solid tumors. Under the terms of the licensing agreement, Knight will be responsible for all commercial activities related to Advaxis current and future products, including axalimogene filolisbac, ADXS-PSA and ADXS-HER2, in Canada. Advaxis is eligible to receive double digit royalty as well as sales milestones.
Advaxis, Inc and MedImmune Commence Enrollment in Phase I/II Study of Axalimogene Filolisbac in Combination With Durvalumab
Aug 20 15
Advaxis, Inc. announced that enrollment has commenced in a phase I/II clinical trial of axalimogene filolisbac (ADXS-HPV), Advaxis's investigational Lm Technology™ immunotherapy, in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), for the treatment of patients with advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer. The two-part, open-label Phase I/II study is designed to evaluate the safety and efficacy of axalimogene filolisbac as a monotherapy and in combination with durvalumab in approximately 66 patients. Phase I is a dose-confirmation combination study with axalimogene filolisbac and durvalumab, which is expected to establish the maximum tolerated dose. The Phase II portion of the study will randomize patients to receive axalimogene filolisbac monotherapy, durvalumab monotherapy, or the combination.
Advaxis, Inc. Appoints Tom Ridge to the Board of Directors
Aug 13 15
Advaxis, Inc. appointed Tom Ridge to the company's Board of Directors. Gov. Ridge currently serves as Chief Executive Officer of Ridge Global, offering clients comprehensive risk evaluation to decrease security risks, with a specific emphasis on helping organizations become cyber resilient.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 26, 2015